Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05300932 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

StatusActive, Not Recruiting
PhasePhase 4
Started2022-03-08
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 27, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-01-25
notable
Recruiting→Active, Not Recruiting Study Status, Sponsor/Collaborators, Contacts/Locations v1
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2023-03→2026-08-01
Completion date2023-04→2026-11-12
Study sitesdetails revised at 2 of 2 sites
Collaborators+168 characters
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Renmin Hospital of Wuhan University Eli Lilly and Company Johns Hopkins University
2022-03-20
minor
Original filing
197 trials monitored
See 2 trials at risk
302 trials monitored
See 9 trials at risk
Systemic Sclerosis (Ssc) is a rare, systemic autoimmune disease characterized by skin fibrosis and vasculopathy. In addition to the skin, it is a heterogeneous disease that affects multiple organs, including the musculoskeletal, cardiac, pulmonary, and gastrointestinal systems. Patients may experience many symptoms such as pain, fatigue, dyspnea, impaired hand function, dry mouth, and difficulty sleeping. As a result of these symptoms, these patients may experience a decrease in activities of daily living, physical activity level and quality of life, while psychological problems such as anxiety and depression may increase.
Trial Details
NCT Number NCT05300932
Lead Sponsor Tongji Hospital
Collaborators: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Renmin Hospital of Wuhan University, Eli Lilly and Company, Johns Hopkins University
Conditions Systemic Sclerosis
Enrollment 60 participants
Start Date 2022-03-08
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-11-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-27